87 related articles for article (PubMed ID: 18604175)
1. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.
Kelber JA; Panopoulos AD; Shani G; Booker EC; Belmonte JC; Vale WW; Gray PC
Oncogene; 2009 Jun; 28(24):2324-36. PubMed ID: 19421146
[TBL] [Abstract][Full Text] [Related]
2. Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis.
Gray PC; Vale W
FEBS Lett; 2012 Jul; 586(14):1836-45. PubMed ID: 22306319
[TBL] [Abstract][Full Text] [Related]
3. Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.
Marzagalli M; Moretti RM; Messi E; Marelli MM; Fontana F; Anastasia A; Bani MR; Beretta G; Limonta P
Sci Rep; 2018 Jan; 8(1):587. PubMed ID: 29330434
[TBL] [Abstract][Full Text] [Related]
4. Whence CRIPTO: The Reemergence of an Oncofetal Factor in 'Wounds' That Fail to Heal.
Freeman DW; Rodrigues Sousa E; Karkampouna S; Zoni E; Gray PC; Salomon DS; Kruithof-de Julio M; Spike BT
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576327
[TBL] [Abstract][Full Text] [Related]
5. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis.
Strizzi L; Bianco C; Normanno N; Salomon D
Oncogene; 2005 Aug; 24(37):5731-41. PubMed ID: 16123806
[TBL] [Abstract][Full Text] [Related]
6. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma.
Strizzi L; Abbott DE; Salomon DS; Hendrix MJ
Cell Cycle; 2008 Jul; 7(13):1931-5. PubMed ID: 18604175
[TBL] [Abstract][Full Text] [Related]
7. Role of Cripto-1 in stem cell maintenance and malignant progression.
Bianco C; Rangel MC; Castro NP; Nagaoka T; Rollman K; Gonzales M; Salomon DS
Am J Pathol; 2010 Aug; 177(2):532-40. PubMed ID: 20616345
[TBL] [Abstract][Full Text] [Related]
8. The threonine that carries fucose, but not fucose, is required for Cripto to facilitate Nodal signaling.
Shi S; Ge C; Luo Y; Hou X; Haltiwanger RS; Stanley P
J Biol Chem; 2007 Jul; 282(28):20133-41. PubMed ID: 17504756
[TBL] [Abstract][Full Text] [Related]
9. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
10. The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics.
Strizzi L; Margaryan NV; Gilgur A; Hardy KM; Normanno N; Salomon DS; Hendrix MJ
Cell Cycle; 2013 May; 12(9):1450-6. PubMed ID: 23574716
[TBL] [Abstract][Full Text] [Related]
11. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.
Gray PC; Shani G; Aung K; Kelber J; Vale W
Mol Cell Biol; 2006 Dec; 26(24):9268-78. PubMed ID: 17030617
[TBL] [Abstract][Full Text] [Related]
12. Ultraviolet radiation and malignant melanoma.
Moan J; Porojnicu AC; Dahlback A
Adv Exp Med Biol; 2008; 624():104-16. PubMed ID: 18348451
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight.
Leiter U; Garbe C
Adv Exp Med Biol; 2008; 624():89-103. PubMed ID: 18348450
[TBL] [Abstract][Full Text] [Related]
14. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells.
Postovit LM; Margaryan NV; Seftor EA; Kirschmann DA; Lipavsky A; Wheaton WW; Abbott DE; Seftor RE; Hendrix MJ
Proc Natl Acad Sci U S A; 2008 Mar; 105(11):4329-34. PubMed ID: 18334633
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
